Respiratory Distress Syndrome - Pipeline Review, H2 2012

Global Markets Direct, July 2012, Pages: 81

Respiratory Distress Syndrome – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Respiratory Distress Syndrome - Pipeline Review, H2 2012', provides an overview of the Respiratory Distress Syndrome therapeutic pipeline. This report provides information on the therapeutic development for Respiratory Distress Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Respiratory Distress Syndrome. 'Respiratory Distress Syndrome - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Respiratory Distress Syndrome.
- A review of the Respiratory Distress Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Respiratory Distress Syndrome pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Respiratory Distress Syndrome.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Respiratory Distress Syndrome pipeline depth and focus of Respiratory Distress Syndrome therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Respiratory Distress Syndrome Therapeutic Products under Development, Key Players in Respiratory Distress Syndrome Therapeutics, Respiratory Distress Syndrome Pipeline Overview, Respiratory Distress Syndrome Pipeline, Respiratory Distress Syndrome Pipeline Assessment

2
List of Tables 5
List of Figures 6
Introduction 7
REPORT COVERAGE 7
Respiratory Distress Syndrome Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Respiratory Distress Syndrome 9
Respiratory Distress Syndrome Therapeutics under Development by Companies 11
Respiratory Distress Syndrome Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Pre-Clinical Stage Products 17
Comparative Analysis 17
Respiratory Distress Syndrome Therapeutics – Products under Development by Companies 18
Respiratory Distress Syndrome Therapeutics – Products under Investigation by Universities/Institutes 19
Companies Involved in Respiratory Distress Syndrome Therapeutics Development 20
Baxter International Inc. 20
GlaxoSmithKline plc 21
Cephalon, Inc. 22
Chiesi Farmaceutici SpA 23
Discovery Laboratories, Inc. 24
Pacgen Biopharmaceuticals Corporation 25
Altor BioScience Corporation 26
ProtAffin Biotechnologie AG 27
Mondobiotech Holding AG 28
Ikaria Inc. 29
Faron Pharmaceuticals, Ltd. 30
Clarassance, Inc. 31
Respiratory Distress Syndrome – Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Combination Products 33
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
SB681323 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Aerosurf - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
PAC-G31P - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
ALT-836 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
IK-6002 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Celestone - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
CHF 5633 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
FP-1201 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
PA401 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Betamethasone - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Insulin - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Surfaxin LS - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Interferon beta for neonatal respiratory distress syndrome - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Surfactant + Vitamin A - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Methylprednisolone - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Anti-MIF Antibody - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
GSK1995057 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
CG367 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
DasKloster 1000–04 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
DasKloster 0141-01 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Respiratory Distress Syndrome Therapeutics – Drug Profile Updates 64
Respiratory Distress Syndrome Therapeutics – Discontinued Products 69
Respiratory Distress Syndrome Therapeutics - Dormant Products 70
Respiratory Distress Syndrome – Product Development Milestones 72
Featured News & Press Releases 72
May 09, 2012: Discovery Labs Announces Publication Of Comparative Study Of Surfaxin LS And Curosurf In Respiratory Distress Syndrome 72
Oct 07, 2011: Faron Completes Phase I/II Clinical Trial With FP-1201 In Acute Lung Injuries 73
Jul 19, 2011: P2D Bioscience Receives NIH Funding To Develop Drugs For Lung Disease 73
Jun 14, 2011: QRxPharma Completes Comparative Safety Study 74
May 23, 2011: Altor BioScience Receives $3m SBIR Phase II Competing Renewal Grant From NHLBI 75
Apr 20, 2011: Discovery Labs’s KL4 Surfactant Aerosolization Program Data To Be Presented At Pediatric Academic Societies Annual Meeting 75
Apr 12, 2011: Faron Completes Recruitment For Phase I/II Clinical Trial Of FP-1201 76
Feb 01, 2011: Discovery Labs Provides Expanded Update For Surfaxin US Marketing Authorization 76
Jan 10, 2011: Discovery Labs Provides Update Regarding Program For Surfaxin US Marketing Authorization 78
Sep 16, 2010: Faron's Lead Product FP-1201 Enters Next Phase Of Study 78
Appendix 80
Methodology 80
Coverage 80
Secondary Research 80
Primary Research 80
Expert Panel Validation 80
Contact Us 81
Disclaimer 81

List of Tables
Number of Products Under Development for Respiratory Distress Syndrome, H2 2012 9
Products under Development for Respiratory Distress Syndrome – Comparative Analysis, H2 2012 10
Number of Products under Development by Companies, H2 2012 12
Number of Products under Investigation by Universities/Institutes, H2 2012 13
Comparative Analysis by Late Stage Development, H2 2012 14
Comparative Analysis by Mid Clinical Stage Development, H2 2012 15
Comparative Analysis by Early Clinical Stage Development, H2 2012 16
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 17
Products under Development by Companies, H2 2012 18
Products under Investigation by Universities/Institutes, H2 2012 19
Baxter International Inc., H2 2012 20
GlaxoSmithKline plc, H2 2012 21
Cephalon, Inc., H2 2012 22
Chiesi Farmaceutici SpA, H2 2012 23
Discovery Laboratories, Inc., H2 2012 24
Pacgen Biopharmaceuticals Corporation, H2 2012 25
Altor BioScience Corporation, H2 2012 26
ProtAffin Biotechnologie AG, H2 2012 27
Mondobiotech Holding AG, H2 2012 28
Ikaria Inc., H2 2012 29
Faron Pharmaceuticals, Ltd., H2 2012 30
Clarassance, Inc., H2 2012 31
Assessment by Monotherapy Products, H2 2012 32
Assessment by Combination Products, H2 2012 33
Assessment by Stage and Route of Administration, H2 2012 35
Assessment by Stage and Molecule Type, H2 2012 37
Respiratory Distress Syndrome Therapeutics – Drug Profile Updates 64
Respiratory Distress Syndrome Therapeutics – Discontinued Products 69
Respiratory Distress Syndrome Therapeutics – Dormant Products 70
Respiratory Distress Syndrome Therapeutics – Dormant Products (Contd..1) 71

List of Figures
Number of Products under Development for Respiratory Distress Syndrome, H2 2012 9
Products under Development for Respiratory Distress Syndrome – Comparative Analysis, H2 2012 10
Products under Development by Companies, H2 2012 11
Products under Investigation by Universities/Institutes, H2 2012 13
Late Stage Products, H2 2012 14
Mid Clinical Stage Products, H2 2012 15
Early Clinical Stage Products, H2 2012 16
Pre-Clinical Stage Products, H2 2012 17
Assessment by Monotherapy Products, H2 2012 32
Assessment by Combination Products, H2 2012 33
Assessment by Route of Administration, H2 2012 34
Assessment by Stage and Route of Administration, H2 2012 35
Assessment by Molecule Type, H2 2012 36
Assessment by Stage and Molecule Type, H2 2012 37

Customers who bought this item also bought

• Acute Respiratory Distress Syndrome - Pipeline Review, H2 2012
• Neonatal Respiratory Distress Syndrome - Pipeline Review, H2 2012
• Acute Respiratory Distress Syndrome (ARDS) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
• Neonatal Respiratory Distress Syndrome Global Clinical Trials Review, H2, 2012
• Acute Respiratory Distress Syndrome Global Clinical Trials Review, H2, 2012
• Neonatal Respiratory Distress Syndrome - Pipeline Review, H2 2011
• Respiratory Distress Syndrome - Pipeline Review, H1 2012
• Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Pipeline Review, H2 2012
• Acute Respiratory Distress Syndrome - Pipeline Review, H1 2013
• Down Syndrome - Pipeline Review, H2 2012